Not every patient with a lung nodule is a candidate for surgical removal. Reduced lung function, cardiac comorbidities, or prior thoracic surgery can make a traditional resection too risky to pursue. Lung tumor ablation has emerged as an option in these situations, using image-guided needle-based techniques to destroy tumor tissue without an open surgical procedure. This article explains how pulmonary ablation is typically used, who it may be considered for, and what risks are associated with treating tumors inside the chest.
How Is Lung Tumor Ablation Performed?
Lung tumor ablation is generally performed percutaneously, meaning the physician advances a thin electrode or probe through the chest wall directly into the lung nodule under CT guidance. Radiofrequency energy, microwave energy, or other thermal techniques are used to heat the targeted tissue to temperatures that cause coagulative necrosis, destroying the tumor cells within the treated zone. The procedure is typically performed with the patient under sedation or general anesthesia, depending on institutional protocol and the location of the nodule. Because the lung is an air-filled organ, imaging characteristics and needle trajectory planning differ somewhat from ablation performed in solid organs such as the liver or kidney.
Who Are Considered Inoperable Patients for Lung Tumors?
The term inoperable patients generally refers to individuals whose overall health, lung function, or cardiac status makes standard surgical resection too risky, even if the tumor itself might otherwise be considered surgically treatable. Chronic obstructive pulmonary disease, prior lung surgery, advanced age combined with comorbidities, and limited cardiopulmonary reserve are commonly cited reasons a multidisciplinary team may steer a patient away from surgery. For some of these patients, ablation is discussed as a treatment option because it avoids general anesthesia risks associated with thoracotomy and does not remove functional lung tissue the way surgical resection does. Whether ablation is appropriate for a specific inoperable patient depends on tumor size, number, and location, and this determination is made by the treating physician.
What Is Pneumothorax Risk and How Is It Managed?
Pneumothorax, a condition in which air accumulates in the space between the lung and the chest wall, is a recognized and commonly reported risk of any needle procedure that passes through lung tissue, including lung tumor ablation. This occurs because the needle track can allow air to leak from the lung into the surrounding pleural space. Symptoms of a significant pneumothorax can include sudden chest pain, shortness of breath, or a feeling of pressure in the chest; patients experiencing these symptoms after a procedure should seek immediate medical care. During and after the procedure, the care team monitors for signs of pneumothorax using imaging and clinical assessment, and small pneumothoraces often resolve without intervention, while larger ones may require a temporary chest tube. This risk is a well-established part of periprocedural planning and monitoring rather than an unpredictable event, and the interventional team accounts for it throughout the procedure.
What Other Considerations Apply to Pulmonary Ablation?
Beyond pneumothorax, other considerations in lung tumor ablation include the tumor's proximity to major airways or blood vessels, the number of nodules being treated in a single session, and the patient's baseline pulmonary function. Tumors located near the chest wall or diaphragm may also require additional planning to protect surrounding structures. As with ablation in other organs, follow-up imaging after the procedure is used to assess the treated area and monitor for any signs of residual or recurrent tumor.
Devices Used in Percutaneous Lung Ablation
Ablation systems used for pulmonary nodules are part of the broader category of percutaneous thermal ablation technology, which includes radiofrequency-based systems within INVAMED's oncology-ablation portfolio. The specific device and technique used for a given lung tumor are selected by the treating physician based on tumor characteristics and institutional protocols. More information on this category of devices is available on the INVAMED oncology ablation products page.
Is lung tumor ablation only used for patients who cannot have surgery?
While inoperable patients are a commonly discussed group for lung ablation, it may also be considered in other clinical scenarios, such as treating a recurrent nodule after prior treatment or addressing a small tumor in a patient who prefers a less invasive option. The decision is individualized and made by the treating physician.
How common is pneumothorax after lung ablation?
Pneumothorax is a commonly reported risk associated with any percutaneous lung procedure, though its frequency and severity vary depending on nodule location, needle path length, and patient lung condition. The care team monitors for this risk throughout the procedure and during recovery.
Does lung tumor ablation replace the need for follow-up scans?
No. Follow-up imaging remains an important part of care after lung tumor ablation, since it helps the care team assess the treated area and monitor for residual or recurrent disease over time. The recommended imaging schedule is determined by the treating physician.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.